Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies (Front. Immunol., (2023), 13, 1093242, 10.3389/fimmu.2022.1093242)

Johannes B. Goll, Steven E. Bosinger, Travis L. Jensen, Hasse Walum, Tyler Grimes, Gregory K. Tharp, Muktha S. Natrajan, Azra Blazevic, Richard D. Head, Casey E. Gelber, Kristen J. Steenbergen, Nirav B. Patel, Patrick Sanz, Nadine G. Rouphael, Evan J. Anderson, Mark J. Mulligan, Daniel F. Hoft

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the published article, there was an error in the Figure 7 legend as published. The figure legend effect size values were incorrectly displayed as “>1.25, 51.5, 51.75, 52” instead of “>1.25, ≥1.5, ≥1.75, ≥2”. The corrected Figure 7 and its caption appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number1163550
JournalFrontiers in immunology
Volume14
DOIs
StatePublished - 2023

Keywords

  • ERCC
  • RNA-Seq
  • gene filtering
  • read length
  • reproducibility
  • sequencing depth
  • statistical power
  • tularemia vaccine (DVC-LVS)

Fingerprint

Dive into the research topics of 'Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies (Front. Immunol., (2023), 13, 1093242, 10.3389/fimmu.2022.1093242)'. Together they form a unique fingerprint.

Cite this